Koala cathelicidin PhciCath5 has antimicrobial activity, including against Chlamydia pecorum

Devastating fires in Australia over 2019–20 decimated native fauna and flora, including koalas. The resulting population bottleneck, combined with significant loss of habitat, increases the vulnerability of remaining koala populations to threats which include disease. Chlamydia is one disease which causes significant morbidity and mortality in koalas. The predominant pathogenic species, Chlamydia pecorum, causes severe ocular, urogenital and reproductive tract disease. In marsupials, including the koala, gene expansions of an antimicrobial peptide family known as cathelicidins have enabled protection of immunologically naïve pouch young during early development. We propose that koala cathelicidins are active against Chlamydia and other bacteria and fungi. Here we describe ten koala cathelicidins, five of which contained full length coding sequences that were widely expressed in tissues throughout the body. Focusing on these five, we investigate their antimicrobial activity against two koala C. pecorum isolates from distinct serovars; MarsBar and IPTaLE, as well as other bacteria and fungi. One cathelicidin, PhciCath5, inactivated C. pecorum IPTaLE and MarsBar elementary bodies and significantly reduced the number of inclusions compared to the control (p<0.0001). Despite evidence of cathelicidin expression within tissues known to be infected by Chlamydia, natural PhciCath5 concentrations may be inadequate in vivo to prevent or control C. pecorum infections in koalas. PhciCath5 also displayed antimicrobial activity against fungi and Gram negative and positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Electrostatic interactions likely drive PhciCath5 adherence to the pathogen cell membrane, followed by membrane permeabilisation leading to cell death. Activity against E. coli was reduced in the presence of 10% serum and 20% whole blood. Future modification of the PhciCath5 peptide to enhance activity, including in the presence of serum/blood, may provide a novel solution to Chlamydia infection in koalas and other species.

[1]  M. Lekka,et al.  Cationic amphipathic peptide analogs of cathelicidin LL‐37 as a probe in the development of antimicrobial/anticancer agents , 2020, Journal of peptide science : an official publication of the European Peptide Society.

[2]  P. Timms,et al.  Helping koalas battle disease – Recent advances in Chlamydia and koala retrovirus (KoRV) disease understanding and treatment in koalas , 2020, FEMS microbiology reviews.

[3]  Huiping Wang,et al.  Chlamydial-Secreted Protease Chlamydia High Temperature Requirement Protein A (cHtrA) Degrades Human Cathelicidin LL-37 and Suppresses Its Anti-Chlamydial Activity , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[4]  H. Cho,et al.  Opossum Cathelicidins Exhibit Antimicrobial Activity Against a Broad Spectrum of Pathogens Including West Nile Virus , 2020, Frontiers in Immunology.

[5]  Ammar Aziz,et al.  Antibiotic treatment of Chlamydia-induced cystitis in the koala is linked to expression of key inflammatory genes in reactive oxygen pathways , 2019, PloS one.

[6]  T. Portas,et al.  Current Therapy in Medicine of Australian Mammals , 2019 .

[7]  P. Timms,et al.  Seventy Years of Chlamydia Vaccine Research – Limitations of the Past and Directions for the Future , 2019, Front. Microbiol..

[8]  G. Zhong,et al.  Chlamydial plasmid-encoded virulence factor Pgp3 interacts with human cathelicidin peptide LL-37 to modulate immune response. , 2019, Microbes and infection.

[9]  P. Timms,et al.  Optimising the short and long-term clinical outcomes for koalas (Phascolarctos cinereus) during treatment for chlamydial infection and disease , 2018, PloS one.

[10]  Graham J. Etherington,et al.  Adaptation and conservation insights from the koala genome , 2018, Nature Genetics.

[11]  K. Rosengren,et al.  Alanine and Lysine Scans of the LL‐37‐Derived Peptide Fragment KR‐12 Reveal Key Residues for Antimicrobial Activity , 2018, Chembiochem : a European journal of chemical biology.

[12]  W. Ellis,et al.  Is disease a major causal factor in declines? An Evidence Framework and case study on koala chlamydiosis , 2018 .

[13]  T. Sorrell,et al.  Marsupial and monotreme cathelicidins display antimicrobial activity, including against methicillin-resistant Staphylococcus aureus. , 2017, Microbiology.

[14]  A. Gillett,et al.  Assessment of florfenicol as a possible treatment for chlamydiosis in koalas (Phascolarctos cinereus) , 2017, Australian veterinary journal.

[15]  A. Potter,et al.  Immunization of a wild koala population with a recombinant Chlamydia pecorum Major Outer Membrane Protein (MOMP) or Polymorphic Membrane Protein (PMP) based vaccine: New insights into immune response, protection and clearance , 2017, PloS one.

[16]  H. Naim,et al.  In vitro activity of human and animal cathelicidins against livestock-associated methicillin-resistant Staphylococcus aureus. , 2016, Veterinary microbiology.

[17]  T. Sorrell,et al.  Cathelicidins in the Tasmanian devil (Sarcophilus harrisii) , 2016, Scientific Reports.

[18]  Xiaomin Song,et al.  Characterisation of the immune compounds in koala milk using a combined transcriptomic and proteomic approach , 2016, Scientific Reports.

[19]  P. Timms,et al.  Chlamydia Serine Protease Inhibitor, targeting HtrA, as a New Treatment for Koala Chlamydia infection , 2016, Scientific Reports.

[20]  M. Kinney,et al.  KOALA RETROVIRUS: A REVIEW , 2016, Journal of Zoo and Wildlife Medicine.

[21]  A. Lesner,et al.  Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015) , 2016, Expert opinion on therapeutic patents.

[22]  Sudhir Kumar,et al.  MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. , 2016, Molecular biology and evolution.

[23]  N. Thomson,et al.  Molecular characterisation of the Chlamydia pecorum plasmid from porcine, ovine, bovine, and koala strains indicates plasmid-strain co-evolution , 2016, PeerJ.

[24]  A. Papenfuss,et al.  The Tasmanian devil microbiome—implications for conservation and management , 2015, Microbiome.

[25]  K.,et al.  Genetic diversity in the plasticity zone and the presence of the chlamydial plasmid differentiates Chlamydia pecorum strains from pigs, sheep, cattle, and koalas , 2015, BMC Genomics.

[26]  G. Zhong,et al.  Chlamydial Plasmid-Encoded Virulence Factor Pgp3 Neutralizes the Antichlamydial Activity of Human Cathelicidin LL-37 , 2015, Infection and Immunity.

[27]  Alexander Dobin,et al.  Mapping RNA‐seq Reads with STAR , 2015, Current protocols in bioinformatics.

[28]  G. Zhong,et al.  Chlamydia-secreted protease CPAF degrades host antimicrobial peptides. , 2015, Microbes and infection.

[29]  A. Roca,et al.  Variation in koala microbiomes within and between individuals: effect of body region and captivity status , 2015, Scientific Reports.

[30]  S. Salzberg,et al.  StringTie enables improved reconstruction of a transcriptome from RNA-seq reads , 2015, Nature Biotechnology.

[31]  M. Wilkins,et al.  A transcriptome resource for the koala (Phascolarctos cinereus): insights into koala retrovirus transcription and sequence diversity , 2014, BMC Genomics.

[32]  G. Myers,et al.  Comparative genomics of koala, cattle and sheep strains of Chlamydia pecorum , 2014, BMC Genomics.

[33]  C. Landersdorfer,et al.  Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation. , 2014, Journal of veterinary pharmacology and therapeutics.

[34]  M. Krockenberger,et al.  Pharmacokinetics of chloramphenicol following administration of intravenous and subcutaneous chloramphenicol sodium succinate, and subcutaneous chloramphenicol, to koalas (Phascolarctos cinereus). , 2013, Journal of veterinary pharmacology and therapeutics.

[35]  P. Timms,et al.  Recent advances in understanding the biology, epidemiology and control of chlamydial infections in koalas. , 2013, Veterinary microbiology.

[36]  E. Veldhuizen,et al.  Chicken Cathelicidins Display Antimicrobial Activity against Multiresistant Bacteria without Inducing Strong Resistance , 2013, PloS one.

[37]  J. Horbańczuk,et al.  Cathelicidins: family of antimicrobial peptides. A review , 2012, Molecular Biology Reports.

[38]  M. Krockenberger,et al.  Plasma concentrations of chloramphenicol after subcutaneous administration to koalas (Phascolarctos cinereus) with chlamydiosis. , 2012, Journal of veterinary pharmacology and therapeutics.

[39]  Yasuhiko Yamamoto,et al.  Long-term surveillance and treatment of subclinical cryptococcosis and nasal colonization by Cryptococcus neoformans and C. gattii species complex in captive koalas (Phascolarctes cinereus). , 2012, Medical mycology.

[40]  K. Nicholas,et al.  Tammar wallaby mammary cathelicidins are differentially expressed during lactation and exhibit antimicrobial and cell proliferative activity. , 2011, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[41]  S. Brunak,et al.  SignalP 4.0: discriminating signal peptides from transmembrane regions , 2011, Nature Methods.

[42]  B. Cocks,et al.  Ancient Antimicrobial Peptides Kill Antibiotic-Resistant Pathogens: Australian Mammals Provide New Options , 2011, PloS one.

[43]  M. Krockenberger,et al.  Absorption of enrofloxacin and marbofloxacin after oral and subcutaneous administration in diseased koalas (Phascolarctos cinereus). , 2010, Journal of veterinary pharmacology and therapeutics.

[44]  N. A. Jacques,et al.  An observational study of the microbiome of the maternal pouch and saliva of the tammar wallaby, Macropus eugenii, and of the gastrointestinal tract of the pouch young. , 2010, Microbiology.

[45]  P. Timms,et al.  Chlamydia trachomatis responds to heat shock, penicillin induced persistence, and IFN-gamma persistence by altering levels of the extracytoplasmic stress response protease HtrA , 2008, BMC Microbiology.

[46]  Kerry A. Daly,et al.  Identification, characterization and expression of cathelicidin in the pouch young of tammar wallaby (Macropus eugenii). , 2008, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[47]  S. Magnino,et al.  Sensitivity of Chlamydia suis to cathelicidin peptides. , 2007, Veterinary microbiology.

[48]  T. Speed,et al.  Characterization of the opossum immune genome provides insights into the evolution of the mammalian immune system. , 2007, Genome research.

[49]  Jonathan M. Harris,et al.  The temperature activated HtrA protease from pathogen Chlamydia trachomatis acts as both a chaperone and protease at 37 °C , 2007 .

[50]  P. Jarman,et al.  Life of Marsupials , 2006 .

[51]  M. Benincasa,et al.  Activity of Cathelicidin Peptides against Chlamydia spp , 2005, Antimicrobial Agents and Chemotherapy.

[52]  P. Yu,et al.  Factors affecting the antimicrobial activity of ovine-derived cathelicidins against E. coli 0157:H7. , 2005, International journal of antimicrobial agents.

[53]  P. McCray,et al.  Reduction in the bactericidal activity of selected cathelicidin peptides by bovine calf serum or exogenous endotoxin. , 2004, International journal of antimicrobial agents.

[54]  U. Wahn,et al.  β-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis , 2004 .

[55]  Robert E W Hancock,et al.  Cationic peptides: distribution and mechanisms of resistance. , 2002, Current pharmaceutical design.

[56]  E. Deane,et al.  Possible antimicrobial compounds from the pouch of the koala,Phascolarctos cinereus , 2001, Letters in Peptide Science.

[57]  R. Gennaro,et al.  Anti-microbial activity and cell binding are controlled by sequence determinants in the anti-microbial peptide PR-39. , 2001, The Journal of investigative dermatology.

[58]  H. Jörnvall,et al.  The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. , 2000, Blood.

[59]  H. Lilja,et al.  The Human Cationic Antimicrobial Protein (hCAP-18) Is Expressed in the Epithelium of Human Epididymis, Is Present in Seminal Plasma at High Concentrations, and Is Attached to Spermatozoa , 2000, Infection and Immunity.

[60]  E. Greenberg,et al.  Bactericidal Activity of Mammalian Cathelicidin-Derived Peptides , 2000, Infection and Immunity.

[61]  Y. Shai,et al.  Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. , 1999, Biochimica et biophysica acta.

[62]  M. Ståhle-Bäckdahl,et al.  The Human Cationic Antimicrobial Protein (hCAP18), a Peptide Antibiotic, Is Widely Expressed in Human Squamous Epithelia and Colocalizes with Interleukin-6 , 1999, Infection and Immunity.

[63]  P. Timms,et al.  Epizootiology of Chlamydia infections in two free-range koala populations. , 1999, Veterinary microbiology.

[64]  K. Berndt,et al.  Conformation-dependent Antibacterial Activity of the Naturally Occurring Human Peptide LL-37* , 1998, The Journal of Biological Chemistry.

[65]  Y. Tsutsumi‐Ishii,et al.  Isolation of cDNA Encoding Guinea Pig Neutrophil Cationic Antibacterial Polypeptide of 11 kDa (CAP11) and Evaluation of CAP11 mRNA Expression during Neutrophil Maturation* , 1997, The Journal of Biological Chemistry.

[66]  J. Cowland,et al.  An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. , 1997, Journal of immunological methods.

[67]  B Yasin,et al.  Protegrins: structural requirements for inactivating elementary bodies of Chlamydia trachomatis , 1996, Infection and immunity.

[68]  E. Wagar,et al.  Susceptibility of Chlamydia trachomatis to protegrins and defensins , 1996, Infection and immunity.

[69]  J. Odeberg,et al.  FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[71]  R. Osawa,et al.  Microflora of the Pouch of the Koala (Phascolarctos cinereus) , 1992, Journal of wildlife diseases.

[72]  F. Carrick,et al.  Use of a dietary supplement in koalas during systemic antibiotic treatment of chlamydial infection. , 1990, Australian veterinary journal.

[73]  G Deléage,et al.  An algorithm for protein secondary structure prediction based on class prediction. , 1987, Protein engineering.

[74]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[75]  F. Bongers,et al.  Implications for conservation and management , 2004 .

[76]  U. Wahn,et al.  Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[77]  R D Appel,et al.  Protein identification and analysis tools in the ExPASy server. , 1999, Methods in molecular biology.

[78]  E. Deane,et al.  Development of the lymphoid tissues of the tammar wallaby Macropus eugenii. , 1997, Reproduction, fertility, and development.

[79]  E. Guiler.  The Tasmanian devil , 1992 .